...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of ophthalmology >Three-monthly intravitreal bevacizumab injections for neovascular age-related macular degeneration: short-term visual acuity results.
【24h】

Three-monthly intravitreal bevacizumab injections for neovascular age-related macular degeneration: short-term visual acuity results.

机译：三个月一次的玻璃体内贝伐单抗注射治疗新生血管性年龄相关性黄斑变性：短期视力结果。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose. To evaluate the change in vision after 3 monthly consecutive intravitreal injections of 1.25 mg of bevacizumab for neovascular age-related macular degeneration (AMD). Methods. A retrospective analysis of 35 eyes was performed. Visual acuity (VA) at initial visit and at each follow-up visit was compared. The injection of bevacizumab was performed at 30-day intervals and patients were observed for 5 months after the last injection. Results. Of the 35 eyes, 9 had received previous treatment with photodynamic therapy with or without 4 mg of intravitreal triamcinolone. VA was measured in Snellen table and transformed into logMAR for statistical purposes. Mean age was 76.66 years (range, 49-90 years). There were 24 (69%) women and 11 (31%) men. Mean VA at the initial visit was 0.92+/-0.50. At month 1, mean VA was 0.84+/-0.51 and at month 2 was 0.74+/-0.51. At month 3, mean VA remained 0.74+/-0.49. Six and 8 months after the initial visit, VA was 0.79+/-0.49 and 0.77+/-0.50, respectively. The improvement in VA was statistically significant at month 2 and at the end of the follow-up (8 months) compared with the baseline VA. Conclusions. Three consecutive monthly injections of intravitreal bevacizumab to treat neovascular AMD is effective in improving VA in the short term. Longer prospective studies should be performed to confirm VA stability after the third injection.
机译：目的。为了评估连续3个月玻璃体内注射1.25 mg贝伐单抗用于新生血管性年龄相关性黄斑变性（AMD）后视力的变化。方法。回顾性分析35只眼。比较初次就诊和每次随访时的视敏度（VA）。贝伐单抗的注射间隔为30天，最后一次注射后观察患者5个月。结果。在35只眼中，有9只曾接受过光动力疗法的治疗，有或没有4 mg玻璃体内曲安奈德。在Snellen表中测量VA，并转换为logMAR以用于统计目的。平均年龄为76.66岁（范围为49-90岁）。有24位女性（69％）和11位男性（31％）。初次就诊时的平均VA为0.92 +/- 0.50。第1个月的平均VA为0.84 +/- 0.51，第2个月的平均VA为0.74 +/- 0.51。在第3个月，平均VA保持在0.74 +/- 0.49。首次访问后六个月和八个月，VA分别为0.79 +/- 0.49和0.77 +/- 0.50。与基线VA相比，VA的改善在第2个月和随访结束时（8个月）有统计学意义。结论连续三个月一次的玻璃体内贝伐单抗注射治疗新血管性AMD，短期内可有效改善VA。第三次注射后应进行更长的前瞻性研究以确认VA的稳定性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号